Abstract
Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-control led, cross-over Study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either close of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. (C) 2009 Movement Disorder Society
| Original language | English |
|---|---|
| Pages (from-to) | 2254-2259 |
| Number of pages | 6 |
| Journal | Movement Disorders |
| Volume | 24 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - 1 Nov 2009 |
Keywords
- cannabinoids
- Huntington's disease
- chorea
- psychiatric symptoms
- nabilone